Literature DB >> 23400077

Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.

Yoichi Sakurada1, Seigo Yoneyama, Mitsuhiro Imasawa, Hiroyuki Iijima.   

Abstract

PURPOSE: To compare the association of systemic risk factors between neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
METHODS: Seven hundred and three patients (235 with nAMD and 468 with PCV) were included. Associated systemic conditions, including hypertension, cardiovascular disease, stroke, diabetes mellitus, and end-stage renal disease, were investigated through an interview and questionnaire.
RESULTS: The prevalence of diabetes mellitus and end-stage renal disease in nAMD was significantly higher than that in PCV (P < 0.001 and P = 0.021, respectively, multivariate logistic regression analysis). Moreover, in diabetic patients with nAMD or PCV, the more severe form of diabetic retinopathy was more prevalent in nAMD cases than in PCV cases (P = 0.006, multivariate logistic regression analysis).
CONCLUSION: Diabetes mellitus and end-stage renal disease are more prevalent in patients with nAMD than in those with PCV. Specific systemic conditions might be associated with the development of nAMD.

Entities:  

Mesh:

Year:  2013        PMID: 23400077     DOI: 10.1097/IAE.0b013e31826ffe9d

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

1.  A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients.

Authors:  Xiao-Li Chen; Qin-Rui Hu; Yu-Jing Bai; Yu Deng; Hai-Wei Wang; Shan Liu; Yin-Lin Wang; Yan-Kun Yue
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

Review 2.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

3.  Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.

Authors:  Nur Afiqah Mohamad; Vasudevan Ramachandran; Patimah Ismail; Hazlita Mohd Isa; Yoke Mun Chan; Nor Fariza Ngah; Norshakimah Md Bakri; Siew Mooi Ching; Fan Kee Hoo; Wan Aliaa Wan Sulaiman
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

4.  Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study.

Authors:  Min Sagong; Se Joon Woo; Youkyung Lee
Journal:  Clin Ophthalmol       Date:  2021-05-11

5.  Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence.

Authors:  Manoj Soman; Indu Nair; Jay U Sheth; Unnikrishnan Nair
Journal:  Ophthalmol Ther       Date:  2022-04-12

6.  Analysis of Genetic and Environmental Risk Factors and Their Interactions in Korean Patients with Age-Related Macular Degeneration.

Authors:  Se Joon Woo; Jeeyun Ahn; Margaux A Morrison; So Yeon Ahn; Jaebong Lee; Ki Woong Kim; Margaret M DeAngelis; Kyu Hyung Park
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 7.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

Review 8.  Aspirin and age related macular degeneration; the possible relationship.

Authors:  Yan Wu; Wei Zhu; Yan-Hong Li; Jing Yu
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

9.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

10.  Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.

Authors:  Ling Liu; Jie Ma; Ping Duan; Yong Liu; Zheng Qin Yin
Journal:  Mol Vis       Date:  2015-10-03       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.